**Supplemental References**

51s. Joolayi F, Navidifar T, Mohammad Jaafari R, Amin M. Comparison of Chlamydia trachomatis infection among infertile and fertile women in Ahvaz, Iran: A case-control study. Int J Reprod BioMed. **2017**; 15(11):713–718.

52s. Tiitinen A, Surcel HM, Halttunen M, et al. Chlamydia trachomatis and chlamydial heat shock protein 60-specific antibody and cell-mediated responses predict tubal factor infertility. Hum Reprod. Oxford University Press; **2006**; 21(6):1533–1538.

53s. Hjelholt A, Christiansen G, Johannesson TG, Ingerslev HJ, Birkelund S. Tubal factor infertility is associated with antibodies against Chlamydia trachomatis heat shock protein 60 (HSP60) but not human HSP60. Hum Reprod. Oxford University Press; **2011**; 26(8):2069–2076.

54s. Woodhall SC, Wills GS, Horner PJ, et al. Chlamydia trachomatis Pgp3 Antibody Population Seroprevalence before and during an Era of Widespread opportunistic chlamydia screening in England (1994-2012). PLoS One. Public Library of Science; **2017**; 12(1).

55s. Petersen MR, Patel EU, Grabowski MK, Gaydos CA, Quinn TC, Tobian AAR. Seroprevalence of Chlamydia trachomatis Among Female Adults in the United States: The National Health and Nutrition Examination Surveys. Clin Infect Dis. NLM (Medline); **2021**; 73(3):e629–e637.

56s. Anyalechi GE, Hong J, Kirkcaldy RD, et al. Chlamydial Pgp3 Seropositivity and Population-Attributable Fraction Among Women With Tubal Factor Infertility. Sex Transm Dis [Internet]. **2022**; 49(8):527–533. Available from: https://journals.lww.com/10.1097/OLQ.0000000000001434

57s. National Institutes of Health. NIH RePORTER [Internet]. Cumulative burden of Chlamydia trachomatis and Mycoplasma genitalium in the US: implications for screening guidelines and antimicrobial resistance. 2022 [cited 2022 Aug 4]. Available from: https://reporter.nih.gov/search/Cc\_kHLC7wUCQ8AKweUyHkw/project-details/10397644

58s. Kaur H, Dize L, Munoz B, Gaydos C, West SK. Evaluation of the reproducibility of a serological test for antibodies to Chlamydia trachomatis pgp3: A potential surveillance tool for trachoma programs. J Microbiol Methods. Elsevier B.V.; **2018**; 147:56–58.

59s. Snoek EM Van Der, Ossewaarde JM, Meijden WI Van Der, Mulder PGH, Thio HB. The use of serological titres of IgA and IgG in (early) discrimination between rectal infection with non-lymphogranuloma venereum and lymphogranuloma venereum serovars of Chlamydia trochomotis. Sex Transm Infect. **2007**; 83(4):330–334.

60s. Alexiou Z. Chlamydia trachomatis IgG seropositivity: who becomes and remains positive? Pathogenesis and prevention of Chlamydia trachomatis infections [Internet]. Chicago: STI & HIV 2023 World Congress; 2023. Available from: https://www.who.int/news-room/fact-sheets/detail/sexually-transmitted-infections-

61s. Öhman H, Tiitinen A, Halttunen M, et al. IL-10 polymorphism and cell-mediated immune response to Chlamydia trachomatis. Genes Immun [Internet]. **2006** [cited 2022 Aug 18]; 7:243–249. Available from: www.nature.com/gene

62s. Öhman H, Tiitinen A, Halttunen M, Paavonen J, Surcel HM. Cytokine gene polymorphism and Chlamydia trachomatis-specific immune responses. Hum Immunol. **2011**; 72(3):278–282.

63s. Nunes A, Gomes JP. Evolution, phylogeny, and molecular epidemiology of Chlamydia. Infection, Genetics and Evolution. **2014**; 23:49–64.

64s. Goodhew EB, Priest JW, Moss DM, et al. CT694 and pgp3 as Serological Tools for Monitoring Trachoma Programs. PLoS Negl Trop Dis. **2012**; 6(11).

65s. Cheong HC, Lee CYQ, Cheok YY, Tan GMY, Looi CY, Wong WF. Chlamydiaceae: Diseases in primary hosts and zoonosis. Microorganisms. MDPI AG; 2019.

66s. Chan PA, Robinette A, Montgomery M, et al. Extragenital Infections Caused by Chlamydia trachomatis and Neisseria gonorrhoeae: A Review of the Literature. Infect Dis Obstet Gynecol [Internet]. **2016** [cited 2022 Aug 23]; 2016:1–17. Available from: http://dx.doi.org/10.1155/2016/5758387

67s. Chandra NL, Broad C, Folkard K, et al. Detection of Chlamydia trachomatis in rectal specimens in women and its association with anal intercourse: a systematic review and meta-analysis. Sex Transm Infect [Internet]. **2018** [cited 2022 Aug 23]; 94:320–326. Available from: http://sti.bmj.com/

68s. Dewart CM, Bernstein KT, Degroote NP, Romaguera R, Turner AN. Prevalence of Rectal Chlamydial and Gonococcal Infections: A Systematic Review HHS Public Access. Sex Transm Dis [Internet]. **2018** [cited 2022 Aug 23]; 45(5):287–293. Available from: http://www.stdjournal.com

69s. Lau A, Kong FYS, Huston W, Chow EPF, Fairley CK, Hocking JS. Factors associated with anorectal Chlamydia trachomatis or Neisseria gonorrhoeae test positivity in women: A systematic review and meta-analysis. Sex Transm Infect. BMJ Publishing Group; **2019**; 95(5):361–367.

70s. Gwyn S, Awoussi MS, Bakhtiari A, et al. Comparison of platforms for testing antibodies to Chlamydia trachomatis antigens in the Democratic Republic of the Congo and Togo. Sci Rep. Nature Research; **2021**; 11(1).

71s. Alexiou ZW, Aar F Van, Hoenderboom BM, Morre SA, Heijne JCM. Trends in Chlamydia trachomatis IgG seroprevalence in the general population of the Netherlands over 20 years. Sex Transm Infect. BMJ Publishing Group; **2023**; 100(1):31-28.

72s. Olsen AW, Follmann F, Erneholm K, Rosenkrands I, Andersen P. Protection Against Chlamydia trachomatis Infection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein. J Infect Dis. Oxford University Press; **2015**; 212(6):978–989.

73s. Rank RG, Batteiger BE. Protective Role of Serum Antibody in Immunity to Chlamydial Genital Infection. Infect Immun. **1989**; 57(1):299–301.

74s. Moore T, Ananaba GA, Bolier J, et al. Fc receptor regulation of protective immunity against Chlamydia trachomatis. Immunology. **2002**; 105:213–221.

75s. Morrison SG, Morrison RP. A Predominant Role for Antibody in Acquired Immunity to Chlamydial Genital Tract Reinfection. J Immunol. **2005**; 175(11):7536–7542.

76s. Su H, Feilzer K, Caldwell HD, Morrison RP. Chlamydia trachomatis Genital Tract Infection of Antibody-Deficient Gene Knockout Mice. Infect Immun. **1997**; 65(6):1993–1999.

77s. Keyt BA, Baliga R, Sinclair AM, Carroll SF, Peterson MS. Structure, function, and therapeutic use of IgM antibodies. Antibodies. MDPI; 2020. p. 1–35.

78s. La Maza LM De, Zhong G, Brunham RC. Update on Chlamydia trachomatis vaccinology. Clinical and Vaccine Immunology. Clin Vaccine Immunol. American Society for Microbiology; **2017**; 24(4).

79s. Morré SA, Munk C, Persson K, et al. Comparison of three commercially available peptide-based immunoglobulin G (IgG) and IgA assays to microimmunofluorescence assay for detection of Chlamydia trachomatis antibodies. J Clin Microbiol. **2002**; 40(2):584–587.

80s. Liu C, Hufnagel K, O’Connell CM, et al. Reduced Endometrial Ascension and Enhanced Reinfection Associated with Immunoglobulin G Antibodies to Specific Chlamydia trachomatis Proteins in Women at Risk for Chlamydia. J Infect Dis. Oxford University Press; **2022**; 225(5):846–855.

81s. Richmond SJ, Caul EO. Fluorescent Antibody Studies in Chlamydial Infections. J Clin Microbiol. American Society for Microbiology. **1975**; 1(4):345–352.

82s. Numazaki K, Chiba S, Yamanaka T, Moroboshi T, Aoki K, Nakao T. Detection of IgM antibodies against Chlamydia trachomatis by enzyme linked fluorescence immunoassay. J Clin Pathol. **1985**; 38:733–739.

83s. Mygind P, Christiansen G, Persson K, Birkelund S. Detection of Chlamydia trachomatis-specific antibodies in human sera by recombinant major outer-membrane protein polyantigens. J Med Microbiol. **2000**; 49(5):457–465.

84s. Kinnunen A, Surcel H-M, Halttunen M, et al. Chlamydial HSP60-induced cytokines in infertile women Chlamydia trachomatis heat shock protein-60 induced interferon-g g g g and interleukin-10 production in infertile women. Clin Exp Immunol. **2003**; 131:299–303.

85s. Svenstrup HF, Fedder J, Kristoffersen SE, Trolle B, Birkelund S, Christiansen G. Mycoplasma genitalium, Chlamydia trachomatis, and tubal factor infertility-a prospective study. Fertil Steril. **2008**; 90(3):513–520.

86s. Rantsi T, Ohman H, Puolakkainen M, et al. Predicting tubal factor infertility by using markers of humoral and cell-mediated immune response against Chlamydia trachomatis. Am J Reprod Immunol. **2018**; 80(e13051).

87s. Toye B, Laferrière C, Claman P, Jessamine P. Association between Antibody to the Chlamydial Heat-Shock Protein and Tubal Infertility. J Infect Dis [Internet]. **1993**; 168(5):1236–1240. Available from: https://about.jstor.org/terms

88s. Peeling RW, Kimani J, Plummer F, et al. Antibody to Chlamydial hsp60 Predicts an Increased Risk for Chlamydial Pelvic Inflammatory Disease. J Infect Dis [Internet]. **1997**; 175:1153–1158. Available from: https://academic.oup.com/jid/article/175/5/1153/853483

89s. Rabenau HF, Köhler E, Peters M, Doerr HW, Weber B. Low Correlation of Serology with Detection of Chlamydia trachomatis by Ligase Chain Reaction and Antigen EIA. Infection. **2000**; 28(2).

90s. Wills GS, Horner PJ, Reynolds R, et al. Pgp3 antibody enzyme-linked immunosorbent assay, a sensitive and specific assay for seroepidemiological analysis of Chlamydia trachomatis infection. Clin Vaccine Immunol. **2009**; 16(6):835–843.

91s. Dize L, Martin D, Gwyn S, Perin J, Gaydos C, Trent M. Comparison of three serological assays to measure antibody response to Chlamydia antigen Pgp3 in adolescent and young adults with pelvic inflammatory disease. Int J STD AIDS. SAGE Publications Ltd; **2018**; 29(13):1324–1329.